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HepG2The TRIB1 locus (8q24.13) is a novel locus identiﬁed and replicated by several genome-wide association studies
for associations with plasma triglycerides, apolipoprotein B and coronary artery disease. The TRIB1 protein prod-
uct, tribbles-like protein 1 (Trib1), regulatesMAPK activity. MAP kinases transduce a large variety of external sig-
nals, leading to awide range of cellular responses, including growth, differentiation, inﬂammation and apoptosis.
Importantly, Trib1 has been shown to regulate hepatic lipogenesis and very low density lipoprotein production.
Despite the relevance of hepatocyte Trib1 to lipid metabolism and atherosclerosis, little is known about the
mechanisms regulating Trib1 itself. Here, we identify the mitochondria axis as a regulator of Trib1. Treatment
of HepG2 cells with a short pulse of a low oligomycin concentration led to a potent and prolonged increase in
the Trib1 mRNA, an effect that was sharedwith other mitochondria stressors. HuH7 cells as well murine hepato-
cytes were also responsive albeit to a weaker extent. The upregulation appeared largely independent of reactive
oxygen species generation ormetabolic stress andwasmainly under transcriptional control, with ERK1/2 playing
an important regulating role in the process.While the presence of the Trib1 protein could be inferred, attempts to
correlate the increasedmRNA to changes in protein level were unsuccessful due to the lack of recognizable Trib1
signal. Our data enrich the current paradigm of Trib1 as an activator of the MAPK pathway by uncovering a role
for MAPK in regulating Trib1.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Coronary disease (CAD) is a complex disorder with multiple etiolo-
gies and a strong heritability component. In the last few years genome
wide association studies (GWAS) from multiple groups have identiﬁed
common alleles robustly linked to CAD [13,22,24,47]. Among the more
than 40 loci recently associated with CAD, is a region located 30 kb
downstream of the Tribbles 1 gene (TRIB1) [47]. The TRIB1 locus has
also been associatedwith increased circulating triglycerides and choles-
terol, decreased high density lipoprotein cholesterol concentration as
well as with hepatic steatosis [9,24,45,48,52]. Consistent with a role in
CAD, TRIB1 protein was reported to be elevated in atherogenic lesions
[46]. Additional efforts using murine models have provided strong
support for a role for TRIB1 in lipid homeostasis and demonstrated
increased lipolysis in a TRIB1 deﬁcient model system [7,40].; CAD, coronary artery disease;
oprotein; ERK1/2, extracellular
PK, mitogen-activated protein
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erson).
ights reserved.At the protein level, TRIB1 (also called C8FW or SKIP1) is a member
of a conserved family of 3 proteins in mammals, with pleiotropic effects
ranging from homeostasis control to cellular proliferation and neurode-
generation [26,36,57]. All 3 members harbor kinase-like domains but
appear inactive due to differences at a key residue [26]. Rather than
functioning as bona ﬁde kinase they appear to interface with, and regu-
late the activity of, effector kinases. More speciﬁcally TRIB1 has been
associated with the anti-apoptotic mitogen-activated protein kinase
(MAPK) pathway [57]. TRIB1 overexpression leads to enhanced ERK1/
2 (MAPK1/3) phosphorylation in various cell types likely via its interac-
tion with MEK1 (MAP2K1) and MKK4 (MAP2K4), two regulators of the
ERK1/2 and JNK pathway, respectively [21,27,46]. In addition to associ-
ating with MEKs, the three Tribbles family members can recruit the
ubiquitin ligase COP1 (constitutive photomorphogenic 1 protein) via a
conserved C-terminal [12]. Recruitment of COP1 by TRIB3 has been
shown to play a pivotal role in lipid mobilization in adipose tissue
[37]. While one can only speculate as to the implications of this interac-
tion for normal TRIB1 function, it is entirely consistent with a role as an
adaptor platform promoting ubiquitination and degradation of cognate
targets, as demonstrated for CEBPα in leukemic cells [12,56].
TRIB1mRNA is widely expressed in a variety of tissues albeit to vary-
ing degrees and is relatively unstable, with a reported half-life of approx-
imately 1 h [27,54]. This instability may help explain why the protein is
expressed at a very low level. While studies so far indicate that all 3
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ly little is known about what regulates their gene expression [57].
The mitochondrial network is involved in a plethora of essential cel-
lular processes ranging from energy generation to apoptosis [3,31]. In
addition mitochondria are both physically and functionally intertwined
with the endoplasmic reticulum [14,15,32]. Although the full extent of
this integration is still incompletely understood, the juxtaposition of
these two organelles appears of paramount importance inmultiple reg-
ulatory systems including calcium signaling and lipid biosynthesis [14].
As the site of ongoing oxidative phosphorylation, the mitochondrial
compartment is continuously generating oxidative radicals, which can
potentially damage multiple cellular targets [58]. Cells have evolved
adaptive systems to deal with reactive oxygen species (ROS) by neutral-
izing enzymatically or chemically the reactive species themselves or
their oxidized products [3]. The mitochondria is itself at the forefront
of this line of defense and interfering with normal mitochondrial func-
tion can generate ROS by uncoupling the respiration complexes present
in the inner mitochondrial membrane or tempering with the ability of
the mitochondria to appropriately address escaped ROS [3].
In view of the importance of mitochondria in the orchestration of
cellular metabolism as well as the implication of TRIB1 in lipid homeos-
tasis, this work investigates the involvement of mitochondria in TRIB1
regulation. Here, we demonstrate that mitochondria dysfunction leads
to increased TRIB1 expression in humanhepatoma cells andmurine hepa-
tocyte cultures and strive to clarify its mechanistic underpinnings. In the
process, we have identiﬁed a contribution of ERK1/2 in regulating both
basal and stimulated TRIB1levels. Thus our work uncovers an unexpected
role for ERK1/2 as a regulator of TRIB1expression, broadening the func-
tional link between the two entities by demonstrating the presence of a
reciprocal regulatory relationship.2. Materials and methods
2.1. Cell culture
HepG2 and HuH7 cells (A.T.C.C.) were maintained in low glucose
DMEM (Dulbecco's modiﬁed Eagle's medium) supplemented with 10%
FBS (fetal bovine serum) and Penicillin/Streptomycin. Amixedmouse he-
patocyte populationwas obtained by dissection of murine livers followed
by plating on ﬁbronectin-coated plates (BD Falcon). Cells were allowed to
recover for 24 h in the above media prior to treatment. TRIB1 silencing
was performed for 48h using either with a 2′-O-(2-methoxy) ethyl anti-
sense oligonucleotide (ISIS Pharmaceuticals) targeting TRIB1 mRNA or a
non-target control (NT) using Lipofectamine RNAiMAX (Invitrogen) es-
sentially as permanufacturer's instructions for RNAi except that a ﬁnal ol-
igonucleotide concentration of 20 nMwas used. Antimycin A, Oligomycin
A, rotenone and the antioxidants were from Sigma. All other inhibitors
were from Cell Signaling. HepG2 stable cell lines were generated by
lentiviral infection with viruses carrying the untagged human TRIB1
ORF or control vector (PLVX).2.2. RNA isolation and qRT-PCR
RNA was isolated and converted to cDNA using the High Pure Iso-
lation Kit (Roche) and the Transcriptor First Strand cDNA Synthesis
Kit (Roche), respectively, following the supplier's guidelines. Ampli-
ﬁcation was performed using the SYBR Green I Master reaction mix
(Roche) on a Roche LightCycler 480. Relative amounts of target
cDNAs were normalized to peptidylprolyl isomerase A (PPIA).
Sequences of the oligonucleotides used are described in the supple-
mental Materials and Methods. Values presented are the mean of 3
biological replicates performed in duplicates (±S.D.). Data are nor-
malized to PPIA and are expressed relative to the control sample
values, set as 100%.2.3. Western blot analysis
Whole cell extracts were lysed in RIPA buffer (50 mM Tris-HCl,
0.15M NaCl, 1% Triton X-100, 0.5% NaDeoxycholate, 0.1% sodium dode-
cyl sulfate, pH7.4) supplemented with 1 X Complete Protease Inhibitor
Tablets and 1 X phoSTOP cocktail (Roche). Lysates (30μg) were cleared
by centrifugation (13,000×g) for 5min at 4 °C and resolved by electro-
phoresis on 4–15% gradient gels. Protein standards were from Bio-Rad
(Precision plus All blue). Proteins were then transferred to nitrocellu-
lose membranes for 90 min at 90 V. Membranes were blocked in 5%
milk and incubated with the various primary antibodies (1:1000 dilu-
tion) for 16h at 4°Cwhile incubationswith thematching secondary an-
tibodies (1:10,000 dilution, LI-COR) were performed for 1 h. Following
each incubation, blots were washed 4×5min in phosphate buffer saline
(PBS). Acquisition was performed on an Odyssey imaging station. Quan-
tiﬁcation was performed using their proprietary software (version
3.0.21). For multiple isoforms (ERK and JNK), the entire population was
quantiﬁed. Primary antibodies used are described in the supplemental
section.
2.4. MitoSOX, Dichlorodihydroﬂuorescein diacetate, tetramethylrhodamine
ethyl (TMRE) and ATP quantiﬁcation assays
HepG2 cells were seeded 24 h prior to assay and ﬂuorescence was
measured in 24well plates on a SynergyMXmicroplate reader (Biotek).
Total ROS were measured using the Image-iT LIVE green Reactive Oxy-
gen Species Detection Kit (which employs 5-(and-6)-carboxy-2′,7′-
dichlorodihydroﬂuorescein diacetate) while mitochondrial oxidation
was measured with MitoSOX Red. Methodology was essentially as sug-
gested by the manufacturer (Molecular Probes). Total ﬂuorescence was
measured in triplicates and corrected for Hoechst 33342 ﬂuorescence,
immediately following the ROS indicators measurements. For mito-
chondria membrane potential measurement, TMRE (0.1 μM) was
added for an additional 15 min following the incubation of HepG2
cells with FCCP and/or OLGM. Wells were brieﬂy rinsed with PBS and
ﬂuorescence was immediately measured using 549 and 575nm for ex-
citation and emission respectively. Correction for cell count was
performed as above, using Hoechst ﬂuorescence. ATP levels were mea-
sured with an ATP determination kit from Molecular Probes. Brieﬂy
HepG2were lysed in RIPA buffer supplemented with 1 X Complete Pro-
tease Inhibitor Tablets, 1 X phoSTOP cocktail (Roche) and 5mMNaF The
cleared supernatants were diluted 100-fold in H2O and immediately
assayed as described by the kit manufacturer (Molecular Probes).
3. Results
3.1. Exposure of HepG2 cells to oligomycin lead to increased
TRIB1mRNA levels
In an initial attempt to identify regulators of TRIB1, we screened
HepG2 cells, a widely used model of hepatic liver cells with modulators
of various cellular pathways; Since mitochondria are parts and parcels
of multiple cellular pathways, well characterized inhibitors of the or-
ganelle were included in the analysis. Oligomycin (OLGM), that inhibits
the mitochondrial ATP synthase, was tested ﬁrst. Low doses of
oligomycin led to a rapid and potent increase in TRIB1 mRNA levels as
assessed by qRT-PCR (Fig. 1, left). Levels were noticeably increased by
2 h and were maximal by 5 h, remaining high until at least 20 h post
treatment (Fig. 1, right). Note that the extent of the maximal stimula-
tion observed appeared to vary somewhat, from 3 to 6 times basal,
which may reﬂect slight differences in OLGM batch and/or cell density.
Given the level of redundancy among the Tribbles family members, we
next compared the effect of TRIB1 to the other members TRIB2 and
TRIB3. While all 3 Tribbles mRNA were upregulated, TRIB1 was signiﬁ-
cantly more affected by OLGM (Supplemental Fig. 1).
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Fig. 1. TRIB1mRNA is upregulated in response to oligomycin treatment in HegG2 cells. Left, dose response. HepG2 cells were treatedwith oligomycin (OLGM) at the indicated doses (μM)
for 1 h and trib1 mRNA levels quantiﬁed 5 h post treatment. Right, time course. TRIB1 mRNA levels were measured at various time points following a 1 h treatment with 0.3 μM OLGM.
3407S. Soubeyrand et al. / Biochimica et Biophysica Acta 1833 (2013) 3405–34143.2. TRIB1 mRNA upregulation occurs in response to multiple OXPHOS
inhibitors and is conserved
In addition to targeting mitochondrial ATP synthase, OLGM has the
potential to affect the Na/K-ATPase, albeit at higher doses (IC50
4.5 μM) or perhaps other uncharacterized OLGM targets as previously
suggested [38,43]. In order to ascertain the putative functional link
between mitochondria and TRIB1, HepG2 were treated with two other
mitochondria speciﬁc drugs Rotenone (Rot) and Antimycin A (Antim).0
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Fig. 2. TRIB1mRNAupregulation occurs in response to othermitochondria-specifc drugs and is c
2 μM) for 1 h and allowed to recover for 5 h prior to RNA isolation. B, HuH7 were treated as in
indicated drugs (in μM) for 1h and chased for either 2 or 5h, as indicated. RNAwas isolated an
ences between samples and control (p b 0.05).Both compounds interfere with respiration by interferingwith complex
I (Rot) or III functions (Antim) [29,51]. Treating HePG2 cells with Antim
or Rot stimulated TRIB1 levels as well, to similar extent similar to what
was observed with OLGM (Fig. 2A). Hence interfering with mitochon-
drial respiration lead to an increase in TRIB1 expression in HepG2 cells.
The prevalence of this response was then examined in another hep-
atoma cell line (HuH7) as well as in primary (murine) hepatocytes
(Fig. 2B, C). HuH7 displayed a TRIB1 response comparable, albeit of
lower magnitude, to that of HepG2 with regard to all three drugs. ByLGM 0.3 OLGM 2 Rot 2 
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onserved. A, Hepg2 cellswere treatedwith AntimycinA (Antim; 0.6μM)or Rotenone (Rot;
A as well as with OLGM (0.3 μM). C, Cells isolated from mouse liver were treated with the
d TRIB1 abundance measured by qRT-PCR. Asterisks indicate statistically signiﬁcant differ-
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Fig. 3. TRIB1mRNA levels are insensitive to antioxidants and exhibit a nuanced response to
mitochondrial membrane potential perturbations. A, HepG2 cells were treated with the
indicated amounts of antioxidants in conjunction with OLGM or vehicle (DMSO) for 1 h.
RNAs were harvested 5 h later and TRIB1 mRNA levels were measured by qRT-PCR. B,
HepG2 were treated OLGM or tert-Butyl Hydroperoxide (tBHP) for 60 min and either
TRIB1 (left) or total cellular ROS levels ormitochondria speciﬁc ROS (right)weremeasured
by DCFDA ormitoSOX, respectively. C, HepG2 cells were pre-treated for 30minwith FCCP
followed, where appropriate, by the inclusion of a 60min OLGM treatment. RNA was iso-
lated 5 h later post-treatment and assessed for TRIB1 and PPIA. D, FCCP controls showing
that a 50μMFCCPpulse results in a signiﬁcant decrease inmembrane potential as assessed
by TMRE ﬂuorescence. Fluorescencewasmeasured immediately after the 1h drug incuba-
tion. Data are the average of n= 3, ±S.D.
3408 S. Soubeyrand et al. / Biochimica et Biophysica Acta 1833 (2013) 3405–3414comparison, primary murine hepatocytes displayed a more nuanced
and transient response to the drugs.
3.3. TRIB1 upregegulation is independent of reactive oxygen species
Next, we turned our attention to the identiﬁcation of proximal
events mediating the observed upregulation. Reactive oxygen species
(ROS) appeared to be a promising initial avenue of investigation since
all three drugs are associated with increased ROS to some extent.
Antimycin A and rotenone treatments of isolated mitochondria lead to
increased ROS generation in the form of superoxide radicals that are
rapidly converted to membrane-permeant hydrogen peroxide by su-
peroxide dismutase in the mitochondrial matrix [29]. Reports on the
impact of Oligomycin treatment on ROS levels differ somewhat, likely
as a function of the system studied [23,29,33].
Contribution of ROS to the TRIB1 increase was tested by the inclusion
of well characterized antioxidants: Trolox, a peroxyl radical scavenger
and Tiron, a superoxide radical anion scavenger [30] and the broad spec-
iﬁcity N-acetylcysteine [2]. As shown in Fig. 3A, all three compounds
failed to attenuate the response, suggesting that the TRIB1 increase
following OLGM treatment cannot be ascribed to oxidative damage.
To evaluate more directly whether oxidative stress alone
can lead to TRIB1 upregulation, HepG2 cells were treated with tert-
butylHydroperoxide (tBHP), a non-speciﬁc ROS generator. An effect on
oxidative stress was ascertained by measuring 2,7-dichloroﬂuorescein
diacetate (DCFDA) andmitoSOX ﬂuorescence, indicators of global cellular
H2O2 level andmitochondria-speciﬁc superoxide anions respectively. Im-
portantly, incubation with tBHP did not affect TRIB1mRNA level despite
leading to increased total H202 and a milder albeit statistically signiﬁcant
(pb0.05) increase in mitochondria-speciﬁc ﬂuorescence (Fig. 3B). Taken
together these data indicate that increased ROS levels are neither neces-
sary nor sufﬁcient to induce TRIB1.
3.4. Oligomycin induction occurs independently of mitochondria inner
membrane potential
Oligomycin may also exert its effect on TRIB1 via a direct impact on
mitochondrial respiration and/ormitochondrial function by causing hy-
perpolarization across the inner mitochondrial membrane [10]. Thus
TRIB1 upregulation could be a direct result of hyperpolarization or
arise from general pertubations in inner mitochondrial polarity. To in-
vestigate the contribution of polarity changes to TRIB1 mRNA, mito-
chondria were depolarized with p-triﬂuoromethoxy carbonylcyanide
phenyl hydrazone (FCCP), in the presence or absence of OLGM. FCCP
also leads to a transient and potent stimulation of respiration as mito-
chondria scramble to regenerate the dissipated proton gradient across
the mitochondrial inner membrane [6]. Interestingly FCCP treatment
alone led to a marginal increase in TRIB1 mRNA albeit at relatively
high doses (Fig. 3C). The increase was associated with a 60% decrease
in membrane potential as assessed by TMRE ﬂuorescence (Fig. 4D). Im-
portantly, FCCP did not affect the extent of the OLGM-induced increase
in TRIB1message indicating that these compounds operate via function-
ally distinct mechanisms.
3.5. TRIB1 increase in response to OLGM is not mediated by established
energy sensors
While short, theOLGMchallenge could conceivably impact the cellu-
lar energy stores by blocking themitochondrial ATP synthase sufﬁcient-
ly to induce a starvation response. Indeed we observe that ATP levels
decreased rapidly, approaching roughly half of its control levels within
1h and remained suppressed for at least another 5h (Fig. 4A). This sug-
gested that TRIB1 upregulation could conceivably arise in response to
declining energy stores. In order to assess the relative contribution of
energy depletion to the TRIB1 increase, we evaluated the contributions
of two pivotal regulators of energy homeostasis AMPK and mTOR(Fig. 4B). AICAR and compound C, which respectively stimulate and in-
hibit AMPK, hadminimal effects on basal TRIB1 levels: AICAR had no sig-
niﬁcant impact on TRIB1while compound C marginally increased TRIB1
mRNA. Similarly there was a signiﬁcant but weak stimulation of basal
TRIB1 levels associated with the mTOR inhibitor Rapamycin. However,
none of these modulators affected the OLGM response noticeably, argu-
ing that the TRIB1 upregulation either does not result from the energetic
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Fig. 4. Interfering with key cell energy sensors fails to curb TRIB1 upregulation. A, Transient OLGM treatment decreases ATP levels in HepG2 cell. ATP levels from HepG2 cells treated with
OLGMor vehicle were assessed using luciferin conversion into oxyluciferin; ATP concentrationswere normalized to the vehicle treated control. Data represent themean of 5 independent
experiments ±S.D. B, Relative amount of TRIB1mRNA in HepG2 pre-treated with rapamycin (RAP), AICAR or compound C (CMPNDC) prior to the addition of OLGM as indicated for 1 h.
RNA was harvested 5 h post treatment. Among the pre-treated samples statistically signiﬁcant differences with Ctl are indicated by an asterisk (P b 0.05, 2-tailed Student t-test).
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shown as a protein load indicator. Only the p54 form of JNK was detectable whereas
both forms of ERK (p42 and p44) were detected. Data is representative of 3 independent
experiments.
3409S. Soubeyrand et al. / Biochimica et Biophysica Acta 1833 (2013) 3405–3414imbalance, is upregulated by a distinct pathway or occurs prior tomTOR
or AMPK activation.
3.6. Implication of the MAPKs in TRIB1 regulation by OLGM
In light of the tight association of the MAPK pathway with TRIB1
(and the Trib proteins in general) and the speciﬁc implication of JNK
in the cellular response to oxidative stress [42], we then examined the
involvement of the various MAPKs in the response of TRIB1 to OLGM.
MAPK activation was ﬁrst assessed by western blot analysis of JNK,
p38 and ERK, using the phosphorylated form as a proxy for the pathway
activation status (Fig. 5). Phosphorylation of all 3 MAPKs increased rap-
idly in response to OLGM, although JNK exhibited a relative delay in this
regard. Kinetically therefore, phosphorylation preceded the maximal
TRIB1 increase (5 h post-treatment), consistent with a role for these
MAPKs in the control of TRIB1mRNA level.
In order to identify which of these pathways, if any, regulates TRIB1
regulation, cells were treated with inhibitors targeting the individual
MAPK pathways: SB203580 for p38, SP600125 for JNK and U0126 for
MEK1/2 (ERK pathway). Among the 3 inhibitors used, only U0126 was
able to abrogate TRIB1 upregulation (Fig. 6A). While SP600125 treat-
ment had little effect, arguing against a role of JNK in the process,
SB203580 increased both basal and OLGM-induced TRIB1 levels to a
small extent, suggesting that the p38 axis may function as a negative
regulator of TRIB1 transcription and/or mRNA stability. Pathway inhibi-
tion was then evaluated by western blot by examining the phosphory-
lation status of the MAPKs (Fig. 6B). The analysis revealed evidence of
interplay between the inhibitors. U0126, which blocks the ERK pathway
upstream of ERK, interfered with both p38 and ERK phosphorylation,
suggesting that ERKmay play a dominant role over p38 in the response
to OLGM. As expected, phosphorylation of p38 and JNK which depends
on upstreamkinases, remained unaffected by their respective inhibitors
SB203580 and SP600125.
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require de novo protein synthesis
Having identiﬁed the plausible basis of the TRIB1mRNA increase, we
next turned our attention to more proximal inquiries, namely the na-
ture of the TRIB1 increase. Increased TRIB1 levels could presumably
ensue from a net stabilization of themessage or enhanced transcription,0
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Fig. 7. TRIB1mRNA stability is regulated at the transcription level and is independent of protein
presence of ActinomycinD (ActinoD; 5μg/ml) as indicated. B, Cellswere treatedwith cyclohexim
assessed by qRT-PCR and normalized to PPIA.or a combination thereof. Of interest, TRIB1mRNA has been reported to
have a short half-life [54] and ERK has been associated with translation
regulation via the ribosomal S6 kinase family [1]. In order to address the
role of transcription in this process, cells previously treated with OLGM
were allowed to recover in the presence of the transcription inhibitor
Actinomycin D. As expected in view of the short half-life of TRIB1
mRNA, Actinomycin D led to a pronounced decrease in TRIB1 messageB
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ide (5μg/ml) andOLGM, either singly or concurrently, as indicated. TRIB1mRNA levelwas
3411S. Soubeyrand et al. / Biochimica et Biophysica Acta 1833 (2013) 3405–3414abundance over the course of the 5h treatment (down to 3% of control
value) (Fig. 7A). Actinomycin D had a similar effect on the OLGM-
treated samples, indicating that the magnitude of the TRIB1 upregula-
tion is largely, if not entirely, under transcriptional control.
The role of de novo protein synthesis and/or translational elongation
in the stabilization of TRIB1 was then investigated by exposing HepG2
cells to the translation inhibitor cycloheximide. Cycloheximide treat-
ment led to a slight increase in basal TRIB1 level but had no signiﬁcant
impact on theOLGM response excluding a requirement for de novo pro-
tein synthesis in the process (Fig. 7B).3.8. Evidence for a functional TRIB1 protein in HepG2 cells
Although TRIB1mRNAwas increased in response to OLGM, effects at
the protein level remained to be investigated. Attemptswere thenmade
to directly measure TRIB1 protein levels by western blot. Importantly
TRIB1 has been reported to be expressed at a very low level, from an un-
stable RNA [54]. Treating HepG2 cells with OLGM did not reveal any
change in protein intensity using two antibodies with distinct speciﬁc-
ities (Fig. 8A). Morover, a profound downregulation of TRIB1 mRNA
levels achieved via the inclusion of U0126 either as a pulse or as a con-
tinuous treatment for 48h, failed to impact the western blot signal no-
ticeably. Integrity and speciﬁcities of the antibodies was conﬁrmed by
detection of TRIB1 in 293 T extracts transiently overexpressing TRIB1
(Fig. 8C). In addition, depletion of TRIB1 mRNA to 40% of its normal
level in HepG2 using TRIB1 speciﬁc antisense oligonucleotide (60%
mRNA knock-down, 48 h) did not alter any detectable signal, even
upon prolonged exposure (Fig. 8C). Attempts to enrich TRIB1 byPonceau
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that TRIB1 down-regulation was always correlated with a decrease in
recovered RNA (47%± 15%, n = 4), consistent with the presence of a
functional TRIB1 protein capable of promoting MAPK and proliferation.
Indeed examining the status of ERK following TRIB1 downregulation re-
vealed a blunted basal ERK phosphorylation (Fig. 8D), conﬁrming the
role of TRIB1 as an important modulator of the MAPK axis and its func-
tional status in HepG2 cells.
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may explain the cross-reactivity observed.4. Discussion
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the regulation of TRIB1 expression by the MAPK pathway, more speciﬁ-
cally the ERK1/2 branch. This observation enriches the currentmodel of
TRIB1 as a MAPK regulator by establishing a positive feedback loop:
TRIB1 activates ERK1/2 which in turn increases TRIB1 levels. Evidently
the feed forward cycle needs to be kept in check and the p38 axis may
be parts and parcel of this regulatory network. This is suggested by
the observation that p38 inhibition with SB203580 led to increased
TRIB1 levels both basally and following OLGM exposure. Yet its role
may be somewhat subservient to that of ERK1/2 as blocking ERK
seemed to block p38 activation, as judged by decreased p38 phosphor-
ylation. Clearly, unraveling the full extent of its contribution to TRIB1
regulation will require further investigation.
The implication of ERK1/2 also appears to place TRIB1 upregulation
in a pathway distinct from the ROS-sensitive JNK/RARα axis [17]. Acti-
vation of this recently described pathway, observed in several model
systems [17,44] results in the inactivation of RARα via a proteasome-
mediated degradation and an ensuing inhibition of its cognate tran-
scription targets. In one study performed in a hepatocyte model
(HuH7), oxidative stress was shown to activate JNK, which in turn led
to RARα degradation [17]. A similar axis, this time involving both RAR
and RXR was demonstrated in cardiomyocites subjected to hyperglyce-
mic conditions and associated radical stress [44]. By contrast, intrinsical-
ly compromised oxidative phosphorylation was shown to trigger a
retrograde signaling from the mitochondria to the nucleus involving
RXRα pathway activation [8]. The characteristics of the TRIB1 response
differ from the JNK/RARα response in 3majorways. First it is a relatively
rapid, whereas the RAR degradation is a longer term process (N6h) and
second, whereas TRIB1 upregulation was clearly ERK1/2 dependent, the
RARαdegradation is not. Lastly, the absence of effect of the JNK inhibitor
appears to exclude JNK activity from the process.
Another question that remains open for future investigations is thena-
ture of the initial event that ultimately results in MAPK activation and
TRIB1 upregulation following the OLGM insult. The low dose of OLGM
used, together with the phenocopying with two other mitochondria-
speciﬁc drugs as well as the impact of membrane potential dissipation
by FCCP, argues in favor of a primary role for the organelle in this respect.
The rapid decline inATP concentration in response toOLGMmight consti-
tute a plausible trigger. Surprisingly however we found that AMPK activ-
ity was not required for the OLGM-mediated increase. AMPK plays a
central role in regulating cellular energy expenditure, is exquisitely sensi-
tive to changes in ATP levels and has been shown to be rapidly activated
by OLGM [16,34,49]. Although our data are inconsistent with a role for
AMPK (or mTOR) in TRIB1 regulation following OLGM exposure, they do
not exclude that ATP depletionmight elicit the response albeit via distinct
mediators which remain to be deﬁned.
Alternatively, or in addition, mitochondrial stress may be directly at
play. While targeting a common pathway, namely the OXPHOS chain,
the 3 mitochondrial inhibitors used in this study bind to different com-
plexes in the chain (complex I, III and V) and as a result somewhat di-
vergent outcomes are to be expected [29,51]. In light of this, our data
seem most consistent with a model where distinct mitochondrial
stresses are recognized and integrated by signaling machineries into a
common response ultimately implicating TRIB1. Of interest, activated
ERK1/2 (and JNK) as well as the MAPK upstream regulatory kinases
Raf and MEK1/2 have been shown to relocate to stressed mitochondria
and may act as early mediators [25,53,55,59]. Our study does not rule
out the contribution of other mediators: we have focused on the re-
sponse to OLGM and whether ERK1/2 mediates TRIB1 upregulation in
response to other mitochondrial stressors (including Rotenone and
Antimycin A) remains to be tested. It remains unclear at present what
the functional implications of the TRIB1 increase are, but the ability of
TRIB1 to activate the MAPK pathway suggests it may be part of a pro-
survival response. Indeed we demonstrate that TRIB1 downregulation
impedes cell proliferation and TRIB1 overexpression protects leukemic
cells from apoptosis [21]. Our attempts to similarly overexpress TRIB1levels in HepG2 cells have yielded no evidence for a protection from
OLGM however (Supplementary Fig. 3). While this does not fully ex-
clude a pro-survival role for TRIB1, it indicates at the very least that it
is not be sufﬁcient in this regard, at least in HepG2 cells.
We demonstrate that the TRIB1mRNA increase in response to OLGM
is largely dependent on steady state transcription. One cannot exclude
at present the possibility that some of the OLGM effect can be ascribed
to mRNA stabilization. Consistent with this idea, mRNA upregulation,
expressed as fold increase due to the presence of OLGM is virtually iden-
tical with or without Actinomycin D. Indeed the 3′ UTR of TRIB1 has been
shown to stabilize TRIB1when expressed in trans [28]. Alternatively, the
residual transcription enhancement could be entirely attributable to a
low level of residual, Actinomycin D-resistant transcription. In any event
OLGM treatment cannot reverse the inherent instability of the message,
the presence of which remains heavily dependent on transcription.
In silico analysis using publicly available data (UCSC gene browser/
ENCODE data) indicates the presence of multiple conserved transcrip-
tion factor binding sites within or in the vicinity of the TRIB1 promoter
region. Of particular interest in view of the involvement of ERK1/2, the
promoter contains a putative binding site for the cAMP responsive ele-
ment binding protein 1 (CREB1), a known target of the ERK pathway via
the RSK kinase [11]. Activation of CREB1 is a key regulatory step distal to
a diverse range of triggers and ultimately results in the transcriptional
activation of multiple, pathway speciﬁc, genes (the CREB regulon)
[19]. Recent work using an epilepsy model has demonstrated that acti-
vation of ERK1/2 and CREB1 do correlate with TRIB1 upregulation fur-
ther lending credence to the role of CREB1 as a distal effector of the
OLGM response [4]. The CEBP familly might also play a role in TRIB1 ex-
pression: the promoter region contains a cognate binding site that can
be enriched by CHIP using antibodies speciﬁc for CEBPα and δ (ChIP-
Seq Uniform Peaks, ENCODE). Furthermore, CEBPα has been reported
to promote the expression of a Trib3 promoter construct and can be ac-
tivated in a ERK1-dependent manner [18,39,41].
One limitation of these experiments is that the endogenous protein
could not be speciﬁcally detected bywestern blot or immunocytochem-
istry (data not shown). This may be due in part to an unstable mRNA
and/or protein or perhaps an inefﬁcient translation. In addition the 5′
UTR of TRIB1 is pyrimidine-rich, consistent with a poor translatability
of the RNA [54]. Current efforts are ongoing in our laboratory to isolate
and characterize endogenously expressed TRIB1.
Both ERK1/2 and TRIB1 play important roles in lipid metabolism: in-
terference with either ERK1/2 or TRIB1 leads to profound changes in
lipid proﬁles [5,7]. Recently, both loci have been linked to adipocyte li-
polysis, albeit in very differentways [20,40]. One experiment uncovered
a novel contribution for macrophage-speciﬁc TRIB1 as its deletion was
sufﬁcient to promote adipose tissue lipolysis and predispose mice to
high-fat induced hypertriglyceridemia [40]. In a second study, Jiao
et al have demonstrated that adipocyte lipolysis and liver beta oxidation
were stimulated by liver-speciﬁc ERK activation [20]. In both studies ad-
ipose tissue lipolysis occurred as a secondary response to distinct organs
and processes, namely aberrant glucose metabolism in the liver and an
altered macrophage population. Hence the underlying regulative path-
ways likely differ signiﬁcantly from each other as well as from our
liver model system. Examination of ERK (in macrophages) and TRIB1
(in liver) as a result of TRIB1 deﬁciency or ERK activation respectively
will help clarify the relationship.
With respect to HepG2 cells, ERK1/2 pathway inhibition lead to a
60% decrease in basal TRIB1 mRNA levels, suggesting that some of the
ERK effects could be mediated by TRIB1. In view of the fact that
inhibiting ERK1/2 can restore an inherent defect in VLDL assembly par-
ticular to HepG2 cells [50], TRIB1 may act in normal hepatocytes as a
negative regulator of VLDL generation via its involvement in the ERK
pathway. According to this scenario MAPK activation would lead to in-
creased TRIB1 levels as well as a repression of VLDL secretion which
could account for the lower circulating VLDL associated with the over-
expression of TRIB1 in a mouse model system [7]. According to this
3413S. Soubeyrand et al. / Biochimica et Biophysica Acta 1833 (2013) 3405–3414model, the contribution of TRIB1would be most likely at the level of
VLDL assembly and/or secretion since liver-speciﬁc MAPK activation
has been shown to decrease expression of genes favoring beta oxidation
[20] which should in turn promote increased VLDL assembly as a result
of fatty acid accumulation.
This appears consistent with the HuH7 data as well. While the re-
sponsiveness to OLGM is shared to some extent with HuH7 (and prima-
ry murine hepatocytes), HepG2 cells are particularly responsive in this
regard. In addition, whereas VLDL lipidation can be corrected in
HepG2 by inhibiting ERK1/2, the picture is different in HuH7 where
lipidation remains deﬁcient [35]. Conceivably, these differences could
be due to differences in the TRIB1/ERK interplay between the two cell
types. Indeed, we did observe that TRIB1 mRNA (relative to both PPIA
and total RNA input) was more abundant in HepG2 than HuH7 (5 to
8-fold by qRT-PCR, data not shown) implying that HepG2 cells may
rely more on TRIB1 for VLDL maturation.
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